Sentences with phrase «studying a drug developed»

Cole has been studying a drug developed to combat parasitic worms in livestock.

Not exact matches

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

LAGUNA NIGUEL, Calif. — The cost to develop and gain FDA approval for a new drug today is more than $ 2.5 billion, according to the Tufts Center for the Study of Drug Developmdrug today is more than $ 2.5 billion, according to the Tufts Center for the Study of Drug DevelopmDrug Development.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Over the past three decades, the Tufts Center for the Study of Drug Development has estimated both the cost and the years it takes for companies to develop new medicines.

«We study the determinants of antimalarial drug quality in developing countries using data from the retail market in Uganda.

The study, published in the January edition of the British Journal of Psychiatry, says spiritual but not religious people, as opposed to people who are religious, agnostic or atheist, were more likely to develop a «mental disorder,» «be dependent on drugs» and «have abnormal eating attitudes,» like bulimia and anorexia.

Could this be because the «School of Pharmacy» at a medical university conducted the study, and is hoping to develop a patent - able drug from the research?

It is possible that the drug is harmful to developing babies, but it's also possible that women who are on antidepressant medications are more severely depressed from the start and there is a biological or behavioral factor in these moms that accounts for the correlation found in the study.

The Academy spent years analyzing all of the available research and ethical issues to develop its official position on the «study drug» matter.

Sugar addiction is a specific type of food addiction and has been shown to develop in animal studies and to have similarities with certain kinds of drug addiction.

Many studies show that once your child starts using a drugs, genetic factors may influence whether they develop an addiction.

A 2012 study published by the Mayo Clinic found that users of marijuana have a smaller chance of developing an addiction to the drug than users of alcohol or tobacco.

Creating and studying peptides that are mirror images of these natural proteins could pave the way to developing such peptides as new drugs with completely different functions from the right - handed versions.

«If you were to develop a drug to treat PTSD, you'd want it to do exactly what MDMA does,» says Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), which funds and conducts the research.

Nondiabetic obese and overweight people lose more weight, are more likely to reverse prediabetes and are slower to develop type 2 diabetes when they take the diabetes drug liraglutide in addition to dieting and exercising, a new study finds.

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.

Dr Sandeep Chhabra from Monash Institute of Pharmaceutical Sciences, said the study will help in developing new drugs to treat autoimmune diseases.

A recent study from a U.K. commission on antimicrobial resistance estimated that by 2050, antibiotic - resistant bacterial infections will kill 10 million people per year, if no new drugs are developed.

The researchers also plan to use this technology to study drug resistance and are developing additional platforms to guide decision making in the clinic.

Now, in a new study using laboratory - grown cells and mice, Johns Hopkins scientists report that a method they used to track metabolic pathways heavily favored by cancer cells provides scientific evidence for combining anti-cancer drugs, including one in a nanoparticle format developed at Johns Hopkins, that specifically target those pathways.

«These findings open doors to developing new drugs against Ebola,» added Zachary Bornholdt, Ph.D., senior staff scientist and first author of the study.

The study findings also associate several other factors with an increased risk of developing BD, including preterm birth, head injury, drug exposures (especially cocaine), physical or sexual abuse, and other forms of stress.

In the past few years, two studies were launched to find out whether drugs that shrink plaques can halt the onset of the disease before symptoms appear in those genetically predisposed to develop Alzheimer's.

Karikó and Weissman founded a company hoping to develop drugs from the discovery, and won nearly a million dollars in small business grants from the U.S. government for animal studies.

Both groups confirmed in genetic, cell, and clinical studies that, for the first time, the parasite had developed resistance to both drugs used in an ACT.

In addition, the investigators found, among the HPTN 052 participants who failed treatment, those who had a higher viral load when they joined the study were more likely to develop resistance to their antiretroviral drugs.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

By increasing the pH of the stomach, PPIs also boost the risk of infection: studies published in JAMA in 2004 and 2005 reported that subjects on acid - suppressing drugs are nearly twice as likely to develop pneumonia, and nearly three times as likely to acquire a potentially deadly infection from the bacterium Clostridium difficile, as unmedicated subjects (although the overall risk is low).

Although it still can not be cured, or even treated very well, several recent studies hint that some treatments — from estrogen to vitamin E to anti-inflammatory drugs — can reduce either the risk of developing the disorder or its symptoms.

In addition, the investigators found that among the HPTN 052 participants who started antiretroviral therapy early but failed treatment before May 2011, those who had a higher viral load when they joined the study were likely to develop resistance to their antiretroviral drugs.

The study was inspired in part by the complex effects of a new melanoma drug developed by the biotech companies Plexxikon and Roche that blocks a protein made by a mutated gene called BRAF.

The study suggests that human knockouts could prove valuable evidence for understanding how genes work and for developing drugs.

To find out if tweaking current overdose protocols could prevent fatal liver damage, Duke mathematicians Lydia Bilinsky and Mike Reed and Duke biologist Fred Nijhout developed a mathematical model of acetaminophen metabolism, based on previous studies of lab rats given high doses of the drug.

The new study builds on a technique developed in 2013 by Sleiman's research group to make nanoscale «cages» from strands of DNA, and stuff them with lipid - like polymer chains that fold together into a ball - shaped particle that can contain cargo such as drug molecules.

«No one's entertained the idea of developing a drug that affects FIH before, but I think our study will lead to greater examination of that possibility,» says Professor Johnson.

In animal and cell culture studies, the drug inhibited growth both in estrogen - dependent breast cancer cells and in cells that had developed resistance to the anti-estrogen tamoxifen and / or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen - dependent breast cancer.

«In this study we mapped the interacting regions in both genes in order to begin the process of developing drugs that can fill in these spaces and block the genes from binding,» says Fisher.

Along with researchers studying nuclear reprogramming and physicians who developed a revolutionary leukemia drug, New York City Mayor Michael Bloomberg won a public service award from the Lasker Foundation today.

«As these drugs are considerably cheaper than current therapies, they can improve treatment in the developing world where the number of deaths from cancer is predicted to increase significantly over the next ten years,» said Dr Federica Sotgia, another leader of the study.

If the study holds up and some miscarriages are in fact due to failure of the fetal cells to produce enough IDO, then drugs might be developed that mimic the enzyme's T cell - dampening effects.

Past studies have shown that when an expectant mother exposes herself to alcohol or drug abuse or she experiences some trauma or illness, her baby may later develop a psychiatric disorder, including some forms of autism or post-traumatic stress disorder, later in life.

By growing organoids from tumor samples, researchers can create minitumors and use them to study how cancer develops or to test drugs.

A study publishing October 1 in Cell Stem Cell reveals why these symptoms arise and tests an investigational drug in mice that could prevent them from developing.

A new study led by University of Kentucky researchers suggests a new approach to develop highly - potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.

While individual researchers and pharmaceutical companies are studying and developing both types of drugs, a major initiative is needed to understand how both drug types might best work together, Sharma and Allison note.

With the advent of genome engineering, scientists are now introducing hundreds of different human mutations in other species to study their effects and develop new drugs.

With good foresight and strategic planning, it could develop into a premier regional center for the study of drug response in Asians — a timely development toward better therapeutics for at least a third of the world's population.

There's a need for ways to find these cells and to study them, and importantly, to develop drugs that target them, because these cancer stem cells are resistant to chemotherapy drugs that target the main tumor.